Please login to the form below
Enhertu
This page shows the latest Enhertu news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to treat unresectable or metastatic HER2-low breast cancer. ... In addition to its indications in breast cancer, Enhertu has also
Latest news
-
AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer
As such, the cost-effectiveness estimates are 'highly uncertain' and Enhertu cannot be recommended for routine use in the NHS. ... Enhertu has therefore been recommended for use within a managed access arrangement, meaning patients can have the treatment
-
AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced gastric cancer
AstraZeneca (AZ) and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) as a monotherapy for adult patients with advanced HER2-positive gastric or gastroesophageal junction ... In DESTINY-Gastric01, Enhertu
-
AstraZeneca to acquire Neogene Therapeutics in $320m deal
This month, it received recommendations for Imfinzi (durvalumab), Enhertu (trastuzumab deruxtecan) and Lynparza (trastuzumab deruxtecan) from the European Medicines Agency’s Committee for Medicinal Products for Human use for the treatment
-
AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza
In DESTINY-Gastric02, updated results showed treatment with Enhertu resulted in a confirmed objective response rate (ORR) of 41.8%. ... Additionally, confirmed ORR was 42.0% with Enhertu versus 12.5% with chemotherapy.
-
AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvements for lung cancer patients
AstraZeneca (AZ) and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) continued to demonstrate clinically meaningful tumour responses in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous ... Enhertu
More from news
Approximately 12 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Putting the ovation into innovation: trends from ESMO
Headline takeaways include:. Enhertu is centre stage and gathering momentum. Enhertu was very present at ESMO, with its potential application getting earlier and broader.
-
Cortellis Drugs to Watch in 2020 report
10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2. ... Enhertu must secure approvals in earlier settings to realise its maximal revenue potential.
-
20 for 2020 – Five pharma companies to watch
advanced or refractory HER2-positive metastatic breast cancer, DS-8201 was recently approved by the FDA with the brand name Enhertu for the treatment of adult patients with unresectable or metastatic
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Kite and Arcellx close multiple myeloma collaboration agreement
- The challenges of identifying rare diseases
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EU outlines measures to mitigate antibiotic shortage across Europe
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EC launches cancer imaging initiative to accelerate innovation and early diagnosis
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- The challenges of identifying rare diseases
- With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
